Incyte Corp (INCY) shareholders
Close on Nov 17, 2026Market cap $24.27BP/E 63.3Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Felix J. Baker Joint filing with Julian C. Baker (15.60%), Baker Bros. Advisors LP (15.40%) and 1 more | 31,225,572 | 15.60% | 13D (active) amendment | May 7, 2026 |
| BlackRock, Inc. | 15,242,171 | 7.80% | 13G (passive) amendment | Sep 30, 2025 |
| Vanguard Capital Management | 12,591,630 | 6.32% | 13G (passive) | Mar 31, 2026 |
| Dodge & Cox | 12,252,356 | 6.20% | 13G (passive) amendment | Mar 31, 2026 |
| State Street Corporation | 9,677,414 | 5.00% | 13G (passive) | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INCY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 30,762,330 | 15.09% | $3.49B | +17,918 | 17.48% |
| BlackRock, Inc. | 18,032,718 | 8.85% | $2.04B | −945,480 | 0.03% |
| Dodge & Cox | 11,957,326 | 5.87% | $1.36B | −295,030 | 0.71% |
| Vanguard Capital Management LLC | 11,024,289 | 5.41% | $1.25B | +94,223 | 0.03% |
| State Street Corp | 9,722,336 | 4.77% | $1.10B | +80,952 | 0.03% |
| Vanguard Portfolio Management LLC | 7,791,091 | 3.82% | $883.20M | +31,908 | 0.04% |
| Aqr Capital Management LLC | 5,320,901 | 2.61% | $603.18M | −487,029 | 0.21% |
| Geode Capital Management, LLC | 4,750,735 | 2.33% | $536.52M | +47,551 | 0.03% |
| Lsv Asset Management | 4,123,759 | 2.02% | $467.47M | +203,703 | 0.85% |
| Invesco Ltd. | 4,080,461 | 2.00% | $462.56M | +209,697 | 0.04% |
| Wellington Management Group Llp | 3,575,521 | 1.75% | $405.32M | +309,385 | 0.07% |
| Renaissance Technologies LLC | 3,512,132 | 1.72% | $398.14M | −139,400 | 0.55% |
| Morgan Stanley | 2,948,364 | 1.45% | $334.23M | +98,036 | 0.02% |
| Arrowstreet Capital, Limited Partnership | 2,744,958 | 1.35% | $311.17M | −85,841 | 0.14% |
| Robeco Institutional Asset Management B.V. | 2,441,735 | 1.20% | $276.80M | −72,648 | 0.34% |
| Goldman Sachs Group Inc | 2,305,782 | 1.13% | $261.38M | −45,439 | 0.02% |
| Dimensional Fund Advisors LP | 2,280,803 | 1.12% | $258.59M | +305,259 | 0.05% |
| Two Sigma Investments, LP | 2,003,559 | 0.98% | $227.12M | +1,587,645 | 0.16% |
| Northern Trust Corp | 1,761,966 | 0.86% | $199.74M | −87,760 | 0.02% |
| Charles Schwab Investment Management Inc | 1,692,439 | 0.83% | $191.85M | −36,663 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 858 | 203M | 99.4% | 125 / 363 | 272 / 71 | 11M | 12M |
| Q1 2026 | 815 | 204M | 100.0% | 109 / 320 | 289 / 104 | 35M | 12M |
| Q4 2025 | 822 | 202M | 98.9% | 175 / 336 | 234 / 49 | 18M | 13M |
| Q3 2025 | 713 | 199M | 97.6% | 126 / 264 | 234 / 63 | 17M | 15M |
| Q2 2025 | 658 | 197M | 96.7% | 101 / 263 | 235 / 63 | 19M | 11M |
| Q1 2025 | 628 | 190M | 93.2% | 73 / 258 | 222 / 83 | 19M | 11M |
| Q4 2024 | 650 | 183M | 89.9% | 125 / 243 | 213 / 57 | 15M | 16M |
| Q3 2024 | 593 | 184M | 90.5% | 83 / 171 | 263 / 69 | 30M | 22M |
| Q2 2024 | 584 | 198M | 97.3% | 73 / 226 | 221 / 68 | 19M | 44M |
| Q1 2024 | 586 | 224M | 100.0% | 88 / 216 | 203 / 52 | 15M | 13M |
| Q4 2023 | 557 | 223M | 100.0% | 98 / 197 | 197 / 61 | 24M | 14M |
| Q3 2023 | 529 | 212M | 100.0% | 51 / 249 | 164 / 47 | 18M | 13M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
774 funds held INCY in Q2 2026, 58% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of INCY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Dodge & Cox Stock Fund | 7,953,128 | 3.90% | $901.57M | 0.76% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 5,390,922 | 2.64% | $611.11M | 0.03% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 4,346,927 | 2.13% | $492.77M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,894,319 | 1.91% | $441.46M | 0.23% | Jun 30, 2026 |
| Vanguard Health Care Fund | 2,386,201 | 1.17% | $285.20M | 0.75% | Jul 31, 2026 |
| iShares Core S&P 500 ETF | 2,309,810 | 1.13% | $261.84M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 2,245,641 | 1.10% | $254.57M | 0.54% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 2,139,308 | 1.05% | $206.96M | 0.02% | May 31, 2026 |
| Invesco S&P 500 Equal Weight ETF | 1,767,886 | 0.87% | $211.30M | 0.22% | Jul 31, 2026 |
| iShares Biotechnology ETF | 1,402,629 | 0.69% | $159.00M | 1.75% | Jun 30, 2026 |
| VictoryShares Free Cash Flow ETF | 1,191,786 | 0.58% | $135.10M | 1.74% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 1,185,538 | 0.58% | $134.39M | 0.33% | Jun 30, 2026 |
| Dodge & Cox Balanced Fund | 1,126,600 | 0.55% | $127.71M | 0.87% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 944,922 | 0.46% | $107.12M | 1.00% | Jun 30, 2026 |
| Vanguard Institutional Index Fund | 910,423 | 0.45% | $103.21M | 0.03% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| William Meury | Chief Executive Officer, Director | 183,129 | 0.09% | Jul 20, 2026 |
| Lee Heeson | EVP, Head of Incyte Intl | 26,884 | 0.01% | Nov 17, 2026 |
| Steven H. Stein | CMO & Head of Late-Stage Dev. | 30,916 | 0.02% | Nov 10, 2026 |
| Thomas Tray | Principal Accounting Officer | 22,525 | 0.01% | Nov 5, 2026 |
| Pablo J. Cagnoni | President, Global Head of R&D | 183,200 | 0.09% | Oct 19, 2026 |
| David H. Gardner | EVP, Chief Strategy Officer | 15,904 | 0.01% | Sep 24, 2026 |
| Ramitpal K. Basi | EVP, Human Resources | 10,993 | 0.01% | Aug 27, 2026 |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 63,648 | 0.03% | Aug 7, 2026 |
| Michael James Morrissey | EVP, Head of Tech. Operations | 34,065 | 0.02% | Jul 27, 2026 |
| Richard A. Hoffman | EVP & General Counsel | 16,861 | 0.01% | Jul 20, 2026 |
| Mohamed Khairie Issa | EVP, Head of U.S. Commercial | 63,940 | 0.03% | Jul 20, 2026 |
| Suketu Upadhyay | EVP & Chief Financial Officer | 26,343 | 0.01% | May 6, 2026 |
| Matteo Trotta | EVP, GM, Dermatology US | 14,882 | 0.01% | Mar 26, 2026 |
| Sheila A. Denton | EVP & General Counsel | 26,569 | 0.01% | Nov 19, 2025 |
| Vijay K. Iyengar | EVP, GMAPPS | 40,540 | 0.02% | Jul 17, 2025 |
| Barry P. Flannelly | EVP & General Manager US | 35,149 | 0.02% | Jul 17, 2025 |
| Paula J. Swain | EVP, Human Resources | 106,482 | 0.05% | Jul 16, 2025 |
| Christiana Stamoulis | EVP & Chief Financial Officer | 125,759 | 0.06% | Jul 16, 2025 |
| Edmund Harrigan | Director | 23,225 | 0.01% | Oct 2, 2026 |
| Bros. Advisors (GP) LLC Baker | Director, 10% owner | 28,497,742 | 13.98% | Oct 2, 2026 |
| Bros. Advisors Lp Baker | Director, 10% owner | 28,487,272 | 13.98% | Oct 2, 2026 |
| 667, L.P. | Director, 10% owner | 3,132,639 | 1.54% | Oct 2, 2026 |
| Brothers Life Sciences LP Baker | Director, 10% owner | 28,502,181 | 13.98% | Oct 2, 2026 |
| Felix Baker | Director, 10% owner | 28,517,943 | 13.99% | Oct 2, 2026 |
| Julian Baker | Director, 10% owner | 33,757,526 | 16.56% | Oct 2, 2026 |
| Paul J. Clancy | Director | 25,838 | 0.01% | Oct 2, 2026 |
| Jacqualyn A. Fouse | Director | 20,968 | 0.01% | Jun 10, 2026 |
| Jean Jacques Bienaime | Director | 24,424 | 0.01% | Jun 10, 2026 |
| Katherine A. High | Director | 14,983 | 0.01% | Jun 10, 2026 |
| Otis W. Brawley | Director | 12,894 | 0.01% | Jun 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lee Heeson EVP, Head of Incyte Intl | Nov 13, 2026 | Sale(10b5-1 plan) | −2,449 | $121.13 | $296.65K | 26,884 |
| Lee Heeson EVP, Head of Incyte Intl | Nov 13, 2026 | Sale(10b5-1 plan) | −3,700 | $120.33 | $445.22K | 29,333 |
| Lee Heeson EVP, Head of Incyte Intl | Nov 13, 2026 | Sale(10b5-1 plan) | −874 | $121.16 | $105.90K | 33,033 |
| Lee Heeson EVP, Head of Incyte Intl | Nov 13, 2026 | Sale(10b5-1 plan) | −2,200 | $120.44 | $264.96K | 33,907 |
| Lee Heeson EVP, Head of Incyte Intl | Nov 13, 2026 | Sale(10b5-1 plan) | −1,471 | $121.89 | $179.30K | 36,107 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Sale(10b5-1 plan) | −48,576 | $119.66 | $5.81M | 30,916 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Sale(10b5-1 plan) | −73,969 | $119.12 | $8.81M | 79,492 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Sale(10b5-1 plan) | −60,270 | $118.27 | $7.13M | 153,461 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Sale(10b5-1 plan) | −22,336 | $117.14 | $2.62M | 213,731 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Sale(10b5-1 plan) | −35,042 | $116.06 | $4.07M | 236,067 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +19,091 | $113.64 | $2.17M | 271,109 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +17,986 | $113.64 | $2.04M | 252,018 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +879 | $113.64 | $99.89K | 234,032 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +24,838 | $83.20 | $2.07M | 233,153 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +15,054 | $83.58 | $1.26M | 208,315 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +12,743 | $90.56 | $1.15M | 193,261 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +16,428 | $85.01 | $1.40M | 180,518 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +6,907 | $68.25 | $471.40K | 164,090 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +12,305 | $64.25 | $790.60K | 157,183 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +19,749 | $61.18 | $1.21M | 144,878 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +18,331 | $61.76 | $1.13M | 125,129 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +23,526 | $77.67 | $1.83M | 106,798 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +15,054 | $74.78 | $1.13M | 83,272 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +16,428 | $80.50 | $1.32M | 68,218 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +12,335 | $72.27 | $891.45K | 51,790 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Nov 6, 2026 | Option exercise | +8,539 | $68.62 | $585.95K | 39,455 |
| Thomas Tray Principal Accounting Officer | Nov 3, 2026 | Sale(10b5-1 plan) | −610 | $118.96 | $72.57K | 21,126 |
| Pablo J. Cagnoni President, Global Head of R&D | Oct 15, 2026 | Sale(10b5-1 plan) | −2,642 | $112.71 | $297.78K | 183,200 |
| Pablo J. Cagnoni President, Global Head of R&D | Oct 15, 2026 | Option exercise | +925 | $64.25 | $59.43K | 185,842 |
| Pablo J. Cagnoni President, Global Head of R&D | Oct 15, 2026 | Option exercise | +455 | $61.18 | $27.84K | 184,917 |
| Pablo J. Cagnoni President, Global Head of R&D | Oct 15, 2026 | Option exercise | +423 | $61.76 | $26.12K | 184,462 |
| Pablo J. Cagnoni President, Global Head of R&D | Oct 15, 2026 | Option exercise | +839 | $71.93 | $60.35K | 184,039 |
| Lee Heeson EVP, Head of Incyte Intl | Oct 1, 2026 | Tax withholding | −463 | $117.14 | $54.24K | 37,578 |
| Paul J. Clancy Director | Sep 30, 2026 | Award | +203 | $121.35 | $24.63K | 25,838 |
| Bros. Advisors Lp Baker Director, 10% owner | Sep 30, 2026 | Award | +322 | – | – | 28,206,082 |
| Bros. Advisors Lp Baker Director, 10% owner | Sep 30, 2026 | Award | +322 | – | – | 2,835,403 |
| Edmund Harrigan Director | Sep 30, 2026 | Award | +206 | $121.35 | $25.00K | 23,225 |
| David H. Gardner EVP, Chief Strategy Officer | Sep 22, 2026 | Tax withholding | −920 | $126.93 | $116.78K | 15,904 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Option exercise | +2,957 | $61.76 | $182.62K | 186,157 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Option exercise | +4,551 | $61.18 | $278.43K | 190,708 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Option exercise | +6,477 | $64.25 | $416.15K | 197,185 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Option exercise | +9,233 | $71.93 | $664.13K | 206,418 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Sale(10b5-1 plan) | −13,985 | $120.49 | $1.69M | 183,200 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Sale(10b5-1 plan) | −9,233 | $120.50 | $1.11M | 197,185 |
| Ramitpal K. Basi EVP, Human Resources | Aug 25, 2026 | Tax withholding | −504 | $129.72 | $65.38K | 10,993 |
| Pablo J. Cagnoni President, Global Head of R&D | Aug 19, 2026 | Sale(10b5-1 plan) | −10,801 | $125.56 | $1.36M | 183,200 |
| Pablo J. Cagnoni President, Global Head of R&D | Aug 12, 2026 | Sale(10b5-1 plan) | −10,803 | $120.04 | $1.30M | 194,001 |
| Pablo J. Cagnoni President, Global Head of R&D | Aug 5, 2026 | Sale(10b5-1 plan) | −10,640 | $122.69 | $1.31M | 204,804 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Aug 5, 2026 | Option exercise | +2,207 | $106.47 | $234.98K | 63,648 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Aug 5, 2026 | Sale(10b5-1 plan) | −2,207 | $123.99 | $273.65K | 61,441 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −6,055 | $120.43 | $729.20K | 61,441 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Aug 3, 2026 | Option exercise | +6,055 | $105.43 | $638.38K | 67,496 |
| Pablo J. Cagnoni President, Global Head of R&D | Jul 31, 2026 | Sale(10b5-1 plan) | −15,888 | $119.70 | $1.90M | 215,444 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +3,148 | $68.62 | $216.02K | 74,687 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +2,709 | $61.76 | $167.31K | 71,539 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +2,284 | $64.25 | $146.75K | 68,830 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +2,918 | $61.18 | $178.52K | 66,546 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −2,293 | $119.41 | $273.81K | 61,441 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −326 | $121.69 | $39.67K | 63,734 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −85 | $122.19 | $10.39K | 64,060 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Incyte's stock actually held short. Settlement fails (shares not delivered on time) peaked at 95,688 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Steven H. Stein Officer | Nov 6, 2026 | 240,193 | $28.35M | Nov 6, 2026 | Exercise of Stock Options |
| Thomas Tray Officer | Nov 3, 2026 | 610 | $73.22K | Nov 3, 2026 | Employee Stock Purchase Plan |
| Pablo J. Cagnoni Officer | Oct 15, 2026 | 2,642 | $297.78K | Oct 15, 2026 | Stock Option Exercise |
| Pablo J. Cagnoni Officer | Sep 15, 2026 | 23,218 | $2.80M | Sep 15, 2026 | Stock Option Exercise |
| Pablo J. Cagnoni Officer | Aug 19, 2026 | 10,801 | $1.36M | Aug 19, 2026 | Restricted Stock and Performance Shares |
| Pablo J. Cagnoni Officer | Aug 12, 2026 | 10,803 | $1.30M | Aug 12, 2026 | Performance and Restricted Stock |
| Pablo J. Cagnoni Officer | Aug 5, 2026 | 10,640 | $1.31M | Aug 5, 2026 | Restricted Stock and Performance Shares |
| Patrick A. Mayes Officer | Aug 5, 2026 | 2,207 | $273.65K | Aug 5, 2026 | Stock Option Exercise |
| Patrick A. Mayes Officer | Aug 3, 2026 | 6,055 | $729.20K | Aug 3, 2026 | Stock Option Exercise |
| Patrick A. Mayes Officer | Jul 31, 2026 | 41,899 | $5.01M | Jul 31, 2026 | Stock Option Exercise |
| Pablo J. Cagnoni Officer | Jul 31, 2026 | 15,888 | $1.90M | Jul 31, 2026 | Restricted Stock |
| Mohamed Khairie Issa Officer | Jul 16, 2026 | 1,093 | $125.71K | Jul 16, 2026 | Restricted Stock |
| Steven H. Stein Officer | Jul 16, 2026 | 1,877 | $215.34K | Jul 16, 2026 | Restricted Stock |
| Steven H. Stein Officer | Jul 15, 2026 | 28,237 | $3.19M | Jul 15, 2026 | Performance Shares |
| Thomas Tray Officer | Jun 4, 2026 | 2,639 | $263.90K | Jun 4, 2026 | Stock Option Exercise |
Congress trades
5 trades in Incyte reported by 4 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Rob Bresnahan PA08 | Sold | May 15, 2025 | $1K–15K | May 31, 2025 |
| Daniel Goldman NY10 | Sold | Mar 6, 2023 | $1K–15K | Apr 17, 2023 |
| Gilbert Cisneros CA31 | Sold | Dec 22, 2020 | $1K–15K | Jan 11, 2021 |
| Gilbert Cisneros CA31 | Bought | Sep 16, 2020 | $1K–15K | Oct 14, 2020 |
| Ed Whitfield KY01 | Bought | Sep 22, 2014 | $1K–15K | Oct 8, 2014 |
See a number that looks wrong?